← Back to Search

Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma

Phase 1
Waitlist Available
Research Sponsored by Celularity Incorporated
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 12 months
Awards & highlights
No Placebo-Only Group

Summary

This trial will study the safety and effectiveness of CYNK-001, a treatment for multiple myeloma made from NK cells derived from the placenta.

Eligible Conditions
  • Lymphoproliferative Disorder
  • Eye Bleeding Disorders
  • Monoclonal Gammopathy
  • Neoplasm
  • Protein Disorder of the Blood
  • Lymphoma
  • Vascular Disease
  • Cardiovascular Disease
  • Cancer
  • Chemotherapy
  • Immune System Disorders
  • Immunoproliferative Disorders
  • Painkillers
  • Sensory System Agents
  • Peripheral Nervous System Agents
  • Hematological Disorders
  • Chorioretinal Vascular Disease
  • Immune Disorders
  • Multiple Myeloma
  • Drug Effects
  • Hemostatic Disorders
  • Paraproteinemia
  • Lymphoproliferative Disorders
  • Hemorrhagic Disorders
  • Blood Diseases
  • Tumors
  • Non-Narcotic Analgesics
  • Blood Protein Disorder

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 12 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Adverse Events (AE)
Dose-Limiting Toxicity (DLT)
Maximum Tolerated Dose (MTD) or Maximum Planned Dose (MPD)
+1 more
Secondary study objectives
International Myeloma Working Group (IMWG) response
Minimal Residual Disease (MRD) Response
Progression-free survival
+5 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Phase IExperimental Treatment1 Intervention
Up to three dosing cohorts of CYNK-001 given on Day 2 or Days 2, 7, 14 post ASCT. Once MTD has been determined, the Expansion cohort will commence.

Find a Location

Who is running the clinical trial?

Celularity IncorporatedLead Sponsor
16 Previous Clinical Trials
598 Total Patients Enrolled
Adrian Kilcoyne, MDStudy DirectorCelularity Incorporated
3 Previous Clinical Trials
163 Total Patients Enrolled
~5 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top